313 related articles for article (PubMed ID: 25738402)
1. Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells.
Yang Q; Zhang S; Kang M; Dong R; Zhao J
Oncol Rep; 2015 May; 33(5):2537-44. PubMed ID: 25738402
[TBL] [Abstract][Full Text] [Related]
2. Combining sorafenib with celecoxib synergistically inhibits tumor growth of non-small cell lung cancer cells in vitro and in vivo.
Zhang H; Li Z; Wang K
Oncol Rep; 2014 Apr; 31(4):1954-60. PubMed ID: 24549815
[TBL] [Abstract][Full Text] [Related]
3. Notch pathway inhibition using DAPT, a γ-secretase inhibitor (GSI), enhances the antitumor effect of cisplatin in resistant osteosarcoma.
Dai G; Deng S; Guo W; Yu L; Yang J; Zhou S; Gao T
Mol Carcinog; 2019 Jan; 58(1):3-18. PubMed ID: 29964327
[TBL] [Abstract][Full Text] [Related]
4. YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.
Kong J; Kong F; Gao J; Zhang Q; Dong S; Gu F; Ke S; Pan B; Shen Q; Sun H; Zheng L; Sun W
Mol Cancer; 2014 Jan; 13():7. PubMed ID: 24418169
[TBL] [Abstract][Full Text] [Related]
5. Dynasore suppresses cell proliferation, migration, and invasion and enhances the antitumor capacity of cisplatin via STAT3 pathway in osteosarcoma.
Zhong B; Shi D; Wu F; Wang S; Hu H; Cheng C; Qing X; Huang X; Luo X; Zhang Z; Shao Z
Cell Death Dis; 2019 Sep; 10(10):687. PubMed ID: 31534119
[TBL] [Abstract][Full Text] [Related]
6. Knockout of ADAM10 enhances sorafenib antitumor activity of hepatocellular carcinoma in vitro and in vivo.
Zhang W; Liu S; Liu K; Ji B; Wang Y; Liu Y
Oncol Rep; 2014 Nov; 32(5):1913-22. PubMed ID: 25176394
[TBL] [Abstract][Full Text] [Related]
7. The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.
Pignochino Y; Dell'Aglio C; Basiricò M; Capozzi F; Soster M; Marchiò S; Bruno S; Gammaitoni L; Sangiolo D; Torchiaro E; D'Ambrosio L; Fagioli F; Ferrari S; Alberghini M; Picci P; Aglietta M; Grignani G
Clin Cancer Res; 2013 Apr; 19(8):2117-31. PubMed ID: 23434734
[TBL] [Abstract][Full Text] [Related]
8. Fisetin, a phytochemical, potentiates sorafenib-induced apoptosis and abrogates tumor growth in athymic nude mice implanted with BRAF-mutated melanoma cells.
Pal HC; Baxter RD; Hunt KM; Agarwal J; Elmets CA; Athar M; Afaq F
Oncotarget; 2015 Sep; 6(29):28296-311. PubMed ID: 26299806
[TBL] [Abstract][Full Text] [Related]
9. Synergistic inhibitory effects of capsaicin combined with cisplatin on human osteosarcoma in culture and in xenografts.
Wang Y; Deng X; Yu C; Zhao G; Zhou J; Zhang G; Li M; Jiang D; Quan Z; Zhang Y
J Exp Clin Cancer Res; 2018 Oct; 37(1):251. PubMed ID: 30326933
[TBL] [Abstract][Full Text] [Related]
10. A CD13 inhibitor, ubenimex, synergistically enhances the effects of anticancer drugs in hepatocellular carcinoma.
Yamashita M; Wada H; Eguchi H; Ogawa H; Yamada D; Noda T; Asaoka T; Kawamoto K; Gotoh K; Umeshita K; Doki Y; Mori M
Int J Oncol; 2016 Jul; 49(1):89-98. PubMed ID: 27121124
[TBL] [Abstract][Full Text] [Related]
11. Meloxicam combined with sorafenib synergistically inhibits tumor growth of human hepatocellular carcinoma cells via ER stress-related apoptosis.
Zhong J; Xiu P; Dong X; Wang F; Wei H; Wang X; Xu Z; Liu F; Li T; Wang Y; Li J
Oncol Rep; 2015 Oct; 34(4):2142-50. PubMed ID: 26252057
[TBL] [Abstract][Full Text] [Related]
12. Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells.
Zhang Y; Zhang B; Zhang A; Zhao Y; Zhao J; Liu J; Gao J; Fang D; Rao Z
Clinics (Sao Paulo); 2012 Sep; 67(9):1093-9. PubMed ID: 23018309
[TBL] [Abstract][Full Text] [Related]
13. Combination of sorafenib and enzalutamide as a potential new approach for the treatment of castration-resistant prostate cancer.
Wu H; Zhang L; Gao X; Zhang X; Duan J; You L; Cheng Y; Bian J; Zhu Q; Yang Y
Cancer Lett; 2017 Jan; 385():108-116. PubMed ID: 27815035
[TBL] [Abstract][Full Text] [Related]
14. The regulation of ERK and p-ERK expression by cisplatin and sorafenib in gastric cancer cells.
Tao C; Lin H; Chen S
Gene; 2014 Nov; 552(1):106-15. PubMed ID: 25219752
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib and 2-Deoxyglucose Synergistically Inhibit Proliferation of Both Sorafenib-Sensitive and -Resistant HCC Cells by Inhibiting ATP Production.
Reyes R; Wani NA; Ghoshal K; Jacob ST; Motiwala T
Gene Expr; 2017 Feb; 17(2):129-140. PubMed ID: 27938509
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib inhibits 5-fluorouracil-resistant gastric cancer cell growth.
Kim HM; Kim SA; Park SB; Cho JH; Song SY
Scand J Gastroenterol; 2017 May; 52(5):577-584. PubMed ID: 28110575
[TBL] [Abstract][Full Text] [Related]
17. Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling.
Wan J; Liu T; Mei L; Li J; Gong K; Yu C; Li W
Br J Cancer; 2013 Jul; 109(2):342-50. PubMed ID: 23807172
[TBL] [Abstract][Full Text] [Related]
18. Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models.
Tesei A; Leonetti C; Zupi G; Scarsella M; Brigliadori G; Ulivi P; Fabbri F; Arienti C; Amadori D; Passardi A; Silvestrini R; Zoli W
J Cell Mol Med; 2011 Feb; 15(2):316-26. PubMed ID: 20015197
[TBL] [Abstract][Full Text] [Related]
19. ABT-263 enhances sorafenib-induced apoptosis associated with Akt activity and the expression of Bax and p21((CIP1/WAF1)) in human cancer cells.
Li J; Chen Y; Wan J; Liu X; Yu C; Li W
Br J Pharmacol; 2014 Jul; 171(13):3182-95. PubMed ID: 24571452
[TBL] [Abstract][Full Text] [Related]
20. Alternol, a natural compound, exerts an anti-tumour effect on osteosarcoma by modulating of STAT3 and ROS/MAPK signalling pathways.
Zuo D; Zhou Z; Wang H; Zhang T; Zang J; Yin F; Sun W; Chen J; Duan L; Xu J; Wang Z; Wang C; Lin B; Fu Z; Liao Y; Li S; Sun M; Hua Y; Zheng L; Cai Z
J Cell Mol Med; 2017 Feb; 21(2):208-221. PubMed ID: 27624867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]